Research Partners


The Centre for Microbial Diseases (CMDR) is a multi-faculty, multi-department consortium of world class microbial diseases and immunology researchers. Its scope encompasses the molecular mechanisms of bacterial, viral, fungal and microbial parasite pathogenesis, host responses to and defences against these agents, basic mechanisms of host immunity, and novel therapeutic and clinical approaches to the treatment of microbial and immunological diseases. The objectives of CMDR are (1) to encourage collaboration among microbial diseases and immunology researchers utilizing different approaches to pursue similar problems, (2) to increase access to research funding by encouraging involvement from the pharmaceutical and biotechnology industries, and by promoting group and collaborative research grant proposals, and (3) to promote graduate and undergraduate education in microbial diseases and immunology.Unable to select database



The Canadian Insitute of Health Research (CIHR) provides funding for four general areas of inquiry: Biomedical Research; Clinical Research: Health Services Research; and Social, Cultural, Environmental and Population Health Research. SPARC provides strategic support services and resources for major CIHR programs, including program outreach, project and proposal development, and proposal review. 


Outcome of UBC townhall meeting - short and long term goals  (forwarded to CIHR Peer Review Working group, July 27th)
UBC's Short and long term goals for CIHR. V2.27July 2016.pdf


UBC VPRI statement on CIHR reforms:




The Centre for Tuberculosis Research (CTBR) at UBC is dedicated to the development of novel therapeutics to curb the effects of the most devastating infectious agent of mortality worldwide, Mycobacterium tuberculosis (Mtb).


The CTBR brings together researchers from UBC's:

  • Faculty of Medicine (departments of Medicine, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology)

  • Faculty of Science (department of Microbiology and Immunology).


The creation of the CTBR allows these researchers to collaborate with each other, build upon each other’s strengths, exchange ideas and data across disciplines and create a stimulating training environment for graduate students and postdocs. The development and optimization of novel anti-bacterials is facilitated through working with the Centre for Drug Research and Development (CDRD).



To promote cutting-edge collaborative opportunities in the disciplines of microbiology, biochemistry, immunology and chemistry to better understand biological processes that can be used as targets for new drugs for tuberculosis chemotherapy.


  • To understand the scientific basis of Mtb’s prevalence, including its inherent resistance to antibiotics and its unusual ability to persist in the host.

  • To develop and optimize novel anti-bacterials that target Mtb.